Pascal Furet

List of Publications by Year in Descending Order

120 papers	9,840 citations	53 h-index	98 g-index
135 ext. papers	10,805 ext. citations	6.1 avg, IF	5.26 L-index

#	Paper	IF	Citations
120	p53 dynamics vary between tissues and are linked with radiation sensitivity. *Nature Communications*, **2021**, 12, 898	17.4	9
119	Identification of FAM181A and FAM181B as new interactors with the TEAD transcription factors. *Protein Science*, **2020**, 29, 509-520	6.3	11
118	A new perspective on the interaction between the Vg/VGLL1-3 proteins and the TEAD transcription factors. *Scientific Reports*, **2020**, 10, 17442	4.9	4
117	Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. *Journal of Medicinal Chemistry*, **2020**, 63, 12542-12573	8.3	20
116	Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation. *Clinical Cancer Research*, **2019**, 25, 3164-3175	12.9	60
115	Structural States of Hdm2 and HdmX: X-ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes. *ChemMedChem*, **2019**, 14, 1305-1314	3.7	9
114	Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson® chorioretinal atrophy. *FEBS Journal*, **2019**, 286, 2381-2398	5.7	12
113	FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer. *Molecular Cancer Therapeutics*, **2019**, 18, 2194-2206	6.1	35
112	2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4. *ACS Medicinal Chemistry Letters*, **2018**, 9, 215-220	4.3	28
111	Adaptation of the bound intrinsically disordered protein YAP to mutations at the YAP:TEAD interface. *Protein Science*, **2018**, 27, 1810-1820	6.3	12
110	Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. *Journal of Medicinal Chemistry*, **2018**, 61, 8120-8135	8.3	144
109	Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201. *Cancer Research*, **2018**, 78, 6257-6267	10.1	38
108	In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 3404-3408	2.9	10
107	Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy. *Biochemistry*, **2018**, 57, 5576-5590	3.2	9
106	Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region. *MedChemComm*, **2017**, 8, 1604-1613	5	18
105	The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. *Nature*, **2017**, 543, 733-737	50.4	256
104	Polyclonal Secondary Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. *Cancer Discovery*, **2017**, 7, 252-263	24.4	262

103	Bioorthogonal Probes for the Study of MDM2-p53 Inhibitors in Cells and Development of High-Content Screening Assays for Drug Discovery. *Angewandte Chemie - International Edition*, **2016**, 55, 16026-16030	16.4	15
102	Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors. *ACS Medicinal Chemistry Letters*, **2016**, 7, 762-7	4.3	33
101	A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis. *Journal of Medicinal Chemistry*, **2016**, 59, 132-46	8.3	26
100	Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 2057-64	2.9	6
99	Bioorthogonal Probes for the Study of MDM2-p53 Inhibitors in Cells and Development of High-Content Screening Assays for Drug Discovery. *Angewandte Chemie*, **2016**, 128, 16260-16264	3.6	3
98	Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 2065-7	2.9	8
97	Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 4837-4841	2.9	47
96	Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 3575-81	2.9	13
95	Identification and optimisation of a 4,5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 3569-74	2.9	13
94	Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 3621-5	2.9	39
93	Discovery of a novel tricyclic 4H-thiazolo[5,4-b]pyrano[2,3-c]pyridine-2-amino scaffold and its application in a PI3K-α inhibitor with high PI3K isoform selectivity and potent cellular activity. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 3582-4	2.9	14
92	Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. *Journal of Medicinal Chemistry*, **2015**, 58, 6348-58	8.3	111
91	A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. *ELife*, **2015**, 4,	8.9	57
90	Author response: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097 **2015**,		2
89	Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 2110-4	2.9	29
88	Characterization of the novel and specific PI3K-α inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. *Molecular Cancer Therapeutics*, **2014**, 13, 1117-29	6.1	288
87	Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial **2014**,		3
86	Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 3741-8	2.9	259

85	The TEAD4-YAP/TAZ protein-protein interaction: expected similarities and unexpected differences. *ChemBioChem*, **2013**, 14, 1218-25	3.8	47
84	The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 3498-502	2.9	60
83	Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. *Journal of Medicinal Chemistry*, **2011**, 54, 7066-83	8.3	310
82	A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. *Cancer Research*, **2011**, 71, 5255-64	10.1	95
81	Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. *Molecular Cancer Therapeutics*, **2010**, 9, 1945-55	6.1	91
80	Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. *Genes and Cancer*, **2010**, 1, 1021-32	2.9	22
79	Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. *Journal of the American Chemical Society*, **2010**, 132, 7043-8	16.4	78
78	The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. *Angiogenesis*, **2010**, 13, 259-67	10.6	87
77	Extended kinase profile and properties of the protein kinase inhibitor nilotinib. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2010**, 1804, 445-53	4	175
76	Design of two new chemotypes for inhibiting the Janus kinase 2 by scaffold morphing. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 1858-60	2.9	7
75	Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2010**, 1804, 454-62	4	51
74	2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 1724-7	2.9	17
73	Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 2609-13	2.9	34
72	New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 3628-31	2.9	15
71	Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway. *Future Medicinal Chemistry*, **2009**, 1, 137-55	4.1	24
70	Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue. *BMC Chemical Biology*, **2009**, 9, 1		58
69	Discovery of a new class of catalytic topoisomerase II inhibitors targeting the ATP-binding site by structure based design. Part I. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 4014-7	2.9	39
68	Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes. *Journal of Biological Chemistry*, **2009**, 284, 8812-21	5.4	58

67	Knowledge-based virtual screening: application to the MDM4/p53 protein-protein interaction. *Methods in Molecular Biology*, **2009**, 575, 173-94	1.4	18
66	Structural Biology Contributions to the Discovery of Drugs to Treat Chronic Myelogenous Leukemia. *NATO Science for Peace and Security Series A: Chemistry and Biology*, **2009**, 37-61	0.1	1
65	Novel, Potent and Selective JAK2 Inhibitors.. *Blood*, **2009**, 114, 3777-3777	2.2	
64	Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. *Blood*, **2008**, 112, 5161-70	2.2	25
63	Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 1027-30	2.9	84
62	Entry into a new class of protein kinase inhibitors by pseudo ring design. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 897-900	2.9	49
61	Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. *Molecular Cancer Therapeutics*, **2008**, 7, 1851-63	6.1	1006
60	Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. *Acta Crystallographica Section D: Biological Crystallography*, **2007**, 63, 80-93		180
59	Novel beta-lactam derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 358-62	2.9	19
58	Verification of a designed intramolecular hydrogen bond in a drug scaffold by nuclear magnetic resonance spectroscopy. *Journal of Medicinal Chemistry*, **2007**, 50, 5875-7	8.3	37
57	Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents. *Journal of Medicinal Chemistry*, **2006**, 49, 4451-4	8.3	26
56	Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. *Mini-Reviews in Medicinal Chemistry*, **2004**, 4, 285-99	3.2	139
55	Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. *Cancer Research*, **2004**, 64, 6385-9	10.1	158
54	In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. *Cancer Cell*, **2004**, 5, 231-9	24.3	468
53	Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 5793-7	2.9	58
52	Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor. *European Journal of Medicinal Chemistry*, **2004**, 39, 11-26	6.8	55
51	Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2004**, 1697, 17-27	4	110
50	Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design. *Journal of Medicinal Chemistry*, **2004**, 47, 4810-3	8.3	53

49	X-ray crystallographic studies of CDK2, a basis for cyclin-dependent kinase inhibitor design in anti-cancer drug research. *Anti-Cancer Agents in Medicinal Chemistry*, **2003**, 3, 15-23		18
48	Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. *Journal of Medicinal Chemistry*, **2003**, 46, 2656-62	8.3	206
47	Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 2967-71	2.9	60
46	Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). *Biochemical Journal*, **2003**, 374, 639-46	3.8	127
45	Protein kinases as targets for anticancer agents: from inhibitors to useful drugs **2002**, 93, 79-98		253
44	Structure-based design and protein X-ray analysis of a protein kinase inhibitor. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 221-4	2.9	43
43	Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 1331-4	2.9	24
42	Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. *Journal of Medicinal Chemistry*, **2002**, 45, 1741-7	8.3	87
41	Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. *Journal of Medicinal Chemistry*, **2002**, 45, 5687-93	8.3	97
40	Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells. *FEBS Letters*, **2002**, 529, 293-7	3.8	30
39	Potent Grb2-SH2 antagonists containing asparagine mimetics **2002**, 573-575		
38	New synthesis of oxcarbazepine via remote metalation of protected N-o-tolyl-anthranilamide derivatives. *Tetrahedron Letters*, **2001**, 42, 385-389	2	27
37	Convergent synthesis of potent peptide inhibitors of the Grb2-SH2 domain by palladium catalyzed coupling of a terminal alkyne. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 1201-3	2.9	10
36	Modeling of the binding mode of a non-covalent inhibitor of the 20S proteasome. Application to structure-based analogue design. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 1321-4	2.9	31
35	Coupling of the antennapedia third helix to a potent antagonist of the p53/hdm2 protein-protein interaction. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 2161-4	2.9	14
34	Tyrosine kinase inhibitors: from rational design to clinical trials. *Medicinal Research Reviews*, **2001**, 21, 499-512	14.4	283
33	Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching. *Journal of Computer-Aided Molecular Design*, **2001**, 15, 489-95	4.2	10
32	STI571: A New Treatment Modality for CML?. *ACS Symposium Series*, **2001**, 245-259	0.4	13

31	Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. *Journal of the National Cancer Institute*, **2001**, 93, 436-46	9.7	91
30	Prospects for Antiangiogenic Therapies Based upon VEGF Inhibition. *ACS Symposium Series*, **2001**, 282-298	3.4	2
29	Total synthesis and biological evaluation of the nakijiquinones. *Journal of the American Chemical Society*, **2001**, 123, 11586-93	16.4	105
28	Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 2337-41	2.9	17
27	Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 2. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 2343-6	2.9	9
26	Structure-based design of potent CDK1 inhibitors derived from olomoucine. *Journal of Computer-Aided Molecular Design*, **2000**, 14, 403-9	4.2	28
25	Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. *Biochemical and Biophysical Research Communications*, **2000**, 275, 877-84	3.4	142
24	A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. *Journal of Molecular Biology*, **2000**, 299, 245-53	6.5	135
23	New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. *Journal of Medicinal Chemistry*, **2000**, 43, 2310-23	8.3	207
22	Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. *Journal of Medicinal Chemistry*, **2000**, 43, 3205-8	8.3	230
21	Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility. *Journal of Biological Chemistry*, **1999**, 274, 23311-5	5.4	44
20	2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **1999**, 9, 91-6	2.9	71
19	Highly potent inhibitors of the Grb2-SH2 domain. *Bioorganic and Medicinal Chemistry Letters*, **1999**, 9, 221-6	2.9	42
18	Structure-based design of a non-peptidic antagonist of the SH2 domain of GRB2. *Bioorganic and Medicinal Chemistry Letters*, **1999**, 9, 1973-8	2.9	17
17	Mapping the X(+1) binding site of the Grb2-SH2 domain with alpha,alpha-disubstituted cyclic alpha-amino acids. *Bioorganic and Medicinal Chemistry Letters*, **1999**, 9, 2915-20	2.9	26
16	Strategies toward the design of novel and selective protein tyrosine kinase inhibitors **1999**, 82, 195-206		290
15	Selective GRB2 SH2 inhibitors as anti-Ras therapy. *International Journal of Cancer*, **1999**, 83, 235-41	7.5	54
14	Structure-based design, synthesis, and X-ray crystallography of a high-affinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic. *Journal of Medicinal Chemistry*, **1999**, 42, 2358-63	8.3	51

13	Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. *Journal of Medicinal Chemistry*, **1999**, 42, 1018-26	8.3	88
12	Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain. *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 2865-70	2.9	23
11	Potent antagonists of the SH2 domain of Grb2: optimization of the X+1 position of 3-amino-Z-Tyr(PO3H2)-X+1-Asn-NH2. *Journal of Medicinal Chemistry*, **1998**, 41, 1741-4	8.3	46
10	Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain. *Journal of Medicinal Chemistry*, **1998**, 41, 3442-9	8.3	86
9	Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands. *Journal of Molecular Biology*, **1998**, 279, 1013-22	6.5	54
8	Dual specificity of Src homology 2 domains for phosphotyrosine peptide ligands. *Biochemistry*, **1997** , 36, 5712-8	3.2	41
7	Discovery of 3-aminobenzyloxycarbonyl as an N-terminal group conferring high affinity to the minimal phosphopeptide sequence recognized by the Grb2-SH2 domain. *Journal of Medicinal Chemistry*, **1997**, 40, 3551-6	8.3	59
6	Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. *Journal of Medicinal Chemistry*, **1997**, 40, 3601-16	8.3	187
5	4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. *Journal of Medicinal Chemistry*, **1996**, 39, 2285-92	8.3	132
4	Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode. *Nature Structural Biology*, **1996**, 3, 586-9		205
3	Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411. *Journal of Computer-Aided Molecular Design*, **1995**, 9, 465-72	4.2	63
2	Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. *FEBS Journal*, **1995**, 234, 317-22		222
1	Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. *Journal of Medicinal Chemistry*, **1994**, 37, 1015-27	8.3	83